dc.contributor.author | Oteo-Iglesias, Jesus | |
dc.contributor.author | Lázaro, Edurne | |
dc.contributor.author | Abajo Iglesias, Francisco J de | |
dc.contributor.author | Baquero, Fernando | |
dc.contributor.author | Campos, Jose | |
dc.date.accessioned | 2020-05-05T08:59:06Z | |
dc.date.available | 2020-05-05T08:59:06Z | |
dc.date.issued | 2005-04 | |
dc.identifier.citation | Emerg Infect Dis. 2005 Apr;11(4):546-53. | es_ES |
dc.identifier.issn | 1080-6040 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/9885 | |
dc.description.abstract | Surveillance System. A network of 32 Spanish hospitals, serving approximately 9.6 million persons, submitted antimicrobial-susceptibility data on 7,098 invasive Escherichia coli species (2001-2003). Resistance to ampicillin, cotrimoxazole, ciprofloxacin, gentamicin, and tobramycin was found at rates of 59.9%, 32.6%, 19.3%, 6.8%, and 5.3%, respectively. Resistance to multiple drugs increased from 13.8% in 2001 to 20.6% in 2003 (p <0.0001). Antimicrobial consumption data were obtained from the Spanish National Health System. In spite of decreased cephalosporin and beta-lactam use, overall extended-spectrum beta-lactamase production increased from 1.6% (2001) to 4.1% (2003) (p <0.0001), mainly due to the rising prevalence of cefotaximases. Resistance to ciprofloxacin significantly increased, mostly in community-onset infections, which coincided with a rise in community quinolone use. Cotrimoxazole resistance remained stable at approximately 30%, even though its use was dramatically reduced. | es_ES |
dc.description.sponsorship | EARSS is funded by the European Commission, DG Sanco (Agreement SI2.123794). This work was supported by research grants MPY 1012/04 (Instituto de Salud Carlos III, Ministry of Health) and SBVI1284/02-13 (Dirección General de Salud Pública, Ministry of Health, Spain). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Centers for Disease Control and Prevention (CDC) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.subject.mesh | Anti-Bacterial Agents | es_ES |
dc.subject.mesh | Drug Resistance, Multiple, Bacterial | es_ES |
dc.subject.mesh | Escherichia coli | es_ES |
dc.subject.mesh | Escherichia coli Infections | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Prospective Studies | es_ES |
dc.subject.mesh | Spain | es_ES |
dc.subject.mesh | Time Factors | es_ES |
dc.subject.mesh | Drug Resistance, Bacterial | es_ES |
dc.title | Antimicrobial-resistant invasive Escherichia coli, Spain | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución-NoComercial-CompartirIgual 4.0 Internacional | * |
dc.identifier.pubmedID | 15829192 | es_ES |
dc.format.volume | 11 | es_ES |
dc.format.number | 4 | es_ES |
dc.format.page | 546-53 | es_ES |
dc.identifier.doi | 10.3201/eid1104.040699 | es_ES |
dc.contributor.funder | Unión Europea. Comisión Europea | |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.contributor.funder | Ministerio de Sanidad y Consumo (España) | |
dc.description.peerreviewed | Sí | es_ES |
dc.relation.publisherversion | https://doi.org/10.3201/eid1104.040699 | es_ES |
dc.identifier.journal | Emerging infectious diseases | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/SI2.123794 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/MPY 1012/04 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/SBVI1284/02-13 | es_ES |
dc.rights.accessRights | open access | es_ES |